Seoulin Bioscience Co.Ltd (038070) — Cash Flow Reinvestment Rate
Seoulin Bioscience Co.Ltd (038070) has a Cash Flow Reinvestment Rate of 3.24x as of December 2025, reinvesting ₩2.05 Billion (capex ₩10.90 Million plus investments ₩-2.04 Billion) from operating cash flow of ₩631.76 Million. See free cash flow generation of Seoulin Bioscience Co.Ltd to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Seoulin Bioscience Co.Ltd Cash Flow Reinvestment Rate (2013–2025)
Historical reinvestment intensity for Seoulin Bioscience Co.Ltd across 11 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Seoulin Bioscience Co.Ltd.
Annual Cash Flow Reinvestment Rate for Seoulin Bioscience Co.Ltd (2013–2025)
Year-by-year capital reinvestment analysis for Seoulin Bioscience Co.Ltd. See 038070 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 3.53x | ₩16.79 Billion | ₩4.76 Billion | ₩507.47 Million | ▼ -88.5% |
| 2023 | 30.63x | ₩28.50 Billion | ₩930.57 Million | ₩974.21 Million | ▲ +723.4% |
| 2021 | 3.72x | ₩33.17 Billion | ₩8.92 Billion | ₩1.67 Billion | ▲ +582.2% |
| 2020 | 0.55x | ₩2.01 Billion | ₩3.68 Billion | ₩401.34 Million | ▲ +60.2% |
| 2019 | 0.34x | ₩2.49 Billion | ₩7.32 Billion | ₩269.29 Million | ▼ -22.9% |
| 2018 | 0.44x | ₩1.84 Billion | ₩4.17 Billion | ₩408.02 Million | ▼ -95.6% |
| 2017 | 10.01x | ₩13.03 Billion | ₩1.30 Billion | ₩8.73 Billion | ▲ +84.0% |
| 2016 | 5.44x | ₩15.00 Billion | ₩2.76 Billion | ₩7.21 Billion | ▲ +401.9% |
| 2015 | 1.08x | ₩4.46 Billion | ₩4.12 Billion | ₩3.74 Billion | ▲ +195.0% |
| 2014 | 0.37x | ₩1.01 Billion | ₩2.74 Billion | ₩761.57 Million | ▲ +3162.2% |
| 2013 | 0.01x | ₩55.65 Million | ₩4.94 Billion | ₩55.65 Million | — |